Rare Disease Day and the rare disease policy, Rare2030

...fragile people, elderly and those with underlying medical conditions or lack of resources are especially at risk

On January 27th, Health Canada announced that all Canadians will be invited to share their views on a national rare disease policy

Many investments have been made into making better predictions and being able to forecast the horizon's future, de-emphasize that we could

On December 16th, 2020, Health Canada announced that it would approve its first-ever gene in Canada - Zolgensma for SMA patients

Our Brazilian team provide important insight into the declaration of a universal health care system, while balancing rare disease treatments

Implications of shortening administrative procedures and investing more money on rare disease research and information sharing.

...if “other costly reforms are shelved, the industry is willing to spend C$1 billion over the same period to boost local manufacturing.

In France, the alarm is being raised: our collective consent to pay for the funding of therapeutic innovation to defeat rare diseases is...

What is our government doing to face the challenges created by new biotechnological innovations that are already knocking on the door?

In the Netherlands, societal debate regularly focuses on drugs for rare diseases. This post begins to uncover the coverage process.

The price tag on many drugs for rare diseases (DRDs) is a significant sticking point for both public and private payers

Overall, Canadians with rare diseases and global citizens alike have been significantly impacted by COVID-19 in many unimaginable ways.

In 2019, with the most recent election of the Trudeau-led Liberal government, the subject of rare diseases received national attention